×
About 4,955 results

ALLMedicine™ Familial Hypercholesterolemia Center

Research & Reviews  1,177 results

How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
https://doi.org/10.5551/jat.RV17063
Journal of Atherosclerosis and Thrombosis; Kataoka Y, Funabashi S et. al.

Jan 14th, 2022 - Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder that elevates low-density lipoprotein cholesterol and increases the risk of premature atherosclerotic cardiovascular disease (ASCVD). However, despite their atherogenic lipid ...

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free ...
https://doi.org/10.1161/JAHA.121.023136
Journal of the American Heart Association; Zheng W, Chilazi M et. al.

Jan 14th, 2022 - Background Accurate measurement of the cholesterol within lipoprotein(a) (Lp[a]-C) and its contribution to low-density lipoprotein cholesterol (LDL-C) has important implications for risk assessment, diagnosis, and treatment of atherosclerotic card...

Screening for Hypercholesterolemia in Children Using Dried Blood Spot.
https://clinicaltrials.gov/ct2/show/NCT05191355

Jan 13th, 2022 - Purpose: Heterozygous Familial Hypercholesterolemia (HeFH) is a common genetic disease responsible for premature atherosclerosis. Therefore, early diagnosis and initiation of a treatment early as at the age of eight years old are recommended to re...

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT04659863

Jan 13th, 2022 - This is a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia ...

see more →

Guidelines  2 results

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 12th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/24335046
Journal of Atherosclerosis and Thrombosis; Teramoto T, Sasaki J et. al.

Dec 18th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

see more →

Drugs  361 results see all →

Clinicaltrials.gov  55 results

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT04659863

Jan 13th, 2022 - This is a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia ...

Screening for Hypercholesterolemia in Children Using Dried Blood Spot.
https://clinicaltrials.gov/ct2/show/NCT05191355

Jan 13th, 2022 - Purpose: Heterozygous Familial Hypercholesterolemia (HeFH) is a common genetic disease responsible for premature atherosclerosis. Therefore, early diagnosis and initiation of a treatment early as at the age of eight years old are recommended to re...

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers
https://clinicaltrials.gov/ct2/show/NCT00001204

Dec 22nd, 2021 - Familial hypercholesterolemia is an autosomal co-dominant disorder resulting in abnormal LDL receptor function, profoundly elevated concentrations of low density lipoproteins, accelerated atherosclerosis and death by early adulthood. This disease ...

Effect of Diet Induced Ketosis on LDL Turnover Rates
https://clinicaltrials.gov/ct2/show/NCT05103761

Nov 9th, 2021 - A ketogenic diet (KD) has recently gained popularity amongst the public due to its ability to induce rapid weight loss and for a number of other putative but unproven health benefits. Ketogenic diets also have proven efficacy in resistant cases of...

Study of Awareness and Detection of Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT01960244

Oct 12th, 2021 - The FH Foundation CASCADE-FH Registry will implement an enrollment framework which is characterized by three possible points of contact: 1) Clinic enrollment 2) Self-enrollment through an online patient portal, and 3) Electronic Health Record (EHR...

see more →

News  384 results

FDA Approves Cholesterol-Lowering siRNA Therapy
https://www.medpagetoday.com/cardiology/prevention/96367

Dec 22nd, 2021 - FDA finally approved inclisiran (Leqvio), making it the first small interfering RNA (siRNA) therapy to hit the market for reducing LDL cholesterol, Novartis announced on Wednesday. The PCSK9 inhibitor was handed an indication as an adjunct to diet...

Fast Five Quiz: Heterozygous Familial Hypercholesterolemia Presentation and Diagnosis
https://www.medscape.com/viewarticle/930070

Dec 22nd, 2021 - Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that results in elevated blood cholesterol levels and a markedly increased risk for atherosclerosis and premature coronary artery disease. Although it is commonly perceiv...

Familial Hypercholesterolemia — Hiding in Plain Sight
https://www.medscape.com/viewarticle/958283

Oct 21st, 2021 - This transcript has been edited for clarity. Laurence Sperling, MD: Welcome to the Medscape InDiscussion podcast series on dyslipidemia. This is the first of six episodes. To launch this series today, we will focus on an extremely important topic:...

Familial Hypercholesterolemia Diagnosed Late, LDL Control Far Below Recommendations
https://www.medscape.com/viewarticle/959861

Sep 30th, 2021 - NEW YORK (Reuters Health) - Globally, familial hypercholesterolemia (FH) is diagnosed late, and control of LDL cholesterol in patients is far below recommendations, a new analysis shows. "Guideline-recommended LDL cholesterol concentrations are in...

FDA Okays Evolocumab Add-On for FH in Children Aged 10 and Up
https://www.medscape.com/viewarticle/959733

Sep 24th, 2021 - The US Food and Drug Administration (FDA) has approved evolocumab (Repatha, Amgen), a PCSK9 inhibitor, for use as add-on treatment to diet alone or with other therapies for children 10 years of age and older with either heterozygous or homozygous ...

see more →

Patient Education  3 results see all →